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Discussion continued:  
More rapid onset and progression of symptoms is associated 
with poorer outcomes.  
There are a few reported world-wide cases of GBS following 
Covid-19 infection. [Rajdev, 2019] 
A review of 37 cases of Covid-19 associated GBS found that the 
mean time to presentation from the onset was 11 days. When 
assessed, albuminocytologic dissociation was found in 76% of 
cases. Serum anti-ganglioside antibodies were absent in the 
majority of cases where assessed. [Caress, 2020]  
GBS is a clinical diagnosis, based on physical exam and history. 
While lumbar puncture results such as cytology can support 
the diagnosis, this confirmation is unnecessary to establish 
diagnosis. The review by Caress of Covid-19 related GBS found 
paresthesias in 68% of cases, limb weakness in 68% of cases 
and cranial nerve symptoms in 35% of cases. [Caress, 2020]]  
Our patient was afebrile and had not preceding respiratory 
symptoms. Patients have also been reported with Covid-19 
associated GBS in which there were no preceding respiratory 
symptoms and no fever. [Scheidl, 2020]. The patient did not 
have loss of taste. Patients with Covid-19 GBS have been 
reported in which there is no loss of taste. [Rana, 2020 
Early detection of GBS may decrease or reverse disease 
progression. Initiation of intravenous immunoglobulin (IVIG) 
therapy is an option. Plasmapheresis is another therapeutic 
option for GBS.  
 
 Conclusions: 
Novel pathogens carry with them new pathologies that 
require elucidation. SARS-CoV-2 exemplifies this idea, and 
has been implicated in a variety of unusual pathologies not 
commonly associated with viral infection. Several cases of 
Guillain-Barre Syndrome associated with Covid-19 have 
been reported. Our case is unique in that the patient did not 
present with any overt signs of Covid-19 infection, such as 
respiratory symptoms. Covid-19 should be considered in any 
patient with acute ascending symmetrical weakness, 
paresthesias, and historical features of GBS; likewise the 
reverse is true, any patient with Covid-19 should receive a 




We report a case of a 72-year-old female who presented 
to the emergency department with a complaint of 
generalized weakness. The patient was found to have 
ascending muscle weakness and subsequently diagnosed 
with Covid-19 related Guillain-Barre Syndrome. Our 
patient was negative for Campylobacter jejuni. It is 
noteworthy that the patient did not have fever, 




 A 72-year-old female presented to the Emergency 
Department (ED) for the evaluation of bilateral lower 
extremity weakness.  Her past medical history included 
sarcoidosis, chronic low back pain, paroxysmal atrial 
fibrillation, hypertension, a non-toxic multinodular goiter  
and thyrotoxicosis  An acute gastrointestinal stool panel 
taken during a recent hospitalization for diverticulitis was 
negative for Campylobacter jejuni. 
She denied subjective fever or chills. She denied 
headache, dizziness, myalgias, change or loss in sense of 
taste, cough or sore throat.  Her vital signs were within 
normal limits. She had absent patellar reflexes bilaterally, 
with a normal Achilles reflex. Muscle strength in bilateral 
lower extremities was 1/5. Sensation in the lower 
extremities was normal.  
On laboratory testing, she was noted to have leukopenia. 
A PCR test for Covid-19 was positive. MRI of the cervical, 
thoracic and lumbar spine revealed no abnormalities that 
could be associated with patient’s presentation. Lumbar 
puncture was unobtainable secondary to chronic 
anticoagulation. A diagnosis of Guillain-Barre Syndrome 
(GBS) was made. The patient was treated with a 5 day 
course of IVIG was initiated in the ED.  The patient’s 
motor strength improved significantly by the time of 
discharge and at the time of out-patient follow up was 




 Covid-19 is a novel coronavirus infection. The most commonly 
associated symptoms are fever, myalgias and respiratory and 
gastrointestinal symptoms. Neurological diagnoses have been 
reported including stroke, headache and dizziness.  
GBS is an acute, generalized polyradiculoneuropathy that has 
been associated with a wide-variety of pathogens, including 
Campylobacter jejuni, EB virus, influenza, CMV and the Zika virus. 
It has been seen after influenza vaccinations. [Caress, 2020]  
GBS is felt to be caused by an autoimmune response that triggers 
a cross-reaction to ganglioside components of peripheral nerves. 
[Scheidl, 2020] 
Most patients with GBS report neurological symptoms within 2 
days to 12 weeks of a diarrheal illness.  Paresthesias may precede 
motor symptoms.  Symptom progression is typically symmetric, 
starting distally. Lower back pain is a common complaint.  Gait 
abnormalities, difficulty standing up are common complaints. 
Deep-tendon reflexes are depressed or absent in the majority of 
patients. Respiratory depression and cranial neuropathy often 
occur later. Symptoms may begin in as little as 12 hours but 
progression past 28 days is very rare.  
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